TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38185589

Group type: EXPERIMENTAL
Intervention: Sintilimab monotherapy
Number of subjects: 71

Group type: COMPARATOR
Intervention: Pembrolizumab monotherapy
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Sintilimab plus platinum-based chemotherapy
Number of subjects: 71

Group type: COMPARATOR
Intervention: Pembrolizumab plus platinum-based chemotherapy
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: All sintilimab-treated patients
Number of subjects: 71

Group type: COMPARATOR
Intervention: All pembrolizumab-treated patients
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Sintilimab plus chemotherapy
Number of subjects: 71

Group type: COMPARATOR
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 71
Study: 38185619

Group type: EXPERIMENTAL
Intervention: Transversalis fascia plane block (TFPB)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Erector spinae plane block (ESPB)
Number of subjects: 80
Study: 38185720

Group type: EXPERIMENTAL
Intervention: Treatment-naïve BC patients
Number of subjects: 112

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 112
Study: 38185760

Group type: EXPERIMENTAL
Intervention: Otoracheal intubation (OTI) during NMOSD-AQP4-IgG+ attacks
Number of subjects: 44
Study: 38185870

Group type: EXPERIMENTAL
Intervention: KidneyIntelX test
Number of subjects: 5348
Study: 38185882

Group type: EXPERIMENTAL
Intervention: CMRGlu classification model
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: CBF classification model
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: GMV classification model
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Combined multi-modal imaging classification model
Number of subjects: 19
Study: 38185920

Group type: EXPERIMENTAL
Intervention: Flexible Ureteroscopic Laser Lithotripsy
Number of subjects: 0
Study: 38186268

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bevacizumab biosimilar
Number of subjects: 0
Study: 38186641

Group type: EXPERIMENTAL
Intervention: New long-acting insulin analog
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38186705

Group type: EXPERIMENTAL
Intervention: Home-based eHealth intervention of cognitively demanding exercise for older adults
Number of subjects: 0
Study: 38187149

Group type: EXPERIMENTAL
Intervention: Moderate-to-severe anemia (Hb <11 g/dL for men and <10 g/dL for women)
Number of subjects: 470

Group type: COMPARATOR
Intervention: No anemia (Hb ≥13 g/dL for men and ≥12 g/dL for women)
Number of subjects: 470

Group type: COMPARATOR
Intervention: Mild anemia (Hb 11-13 g/dL for men and 10-12 g/dL for women)
Number of subjects: 470
Study: 38187797

Group type: EXPERIMENTAL
Intervention: Individual family counseling and participation in nutrition courses and physical activity groups
Number of subjects: 137
Study: 38187863

Group type: EXPERIMENTAL
Intervention: Telazorlimab 300 mg every 2 weeks (part 1)
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Telazorlimab 600 mg every 2 weeks (part 2)
Number of subjects: 462

Group type: COMPARATOR
Intervention: Placebo (part 1)
Number of subjects: 462

Group type: COMPARATOR
Intervention: Placebo (part 2)
Number of subjects: 462
Study: 38188047

Group type: EXPERIMENTAL
Intervention: Machine learning algorithm for care intensity allocation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multi-professional care team for care intensity allocation
Number of subjects: 0
Study: 38188262

Group type: EXPERIMENTAL
Intervention: Vaccine counseling in ICU recovery clinics (ICU-RCs)
Number of subjects: 32
Study: 38188275

Group type: EXPERIMENTAL
Intervention: Onlay mesh
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Sublay mesh
Number of subjects: 480

Group type: COMPARATOR
Intervention: Primary suture
Number of subjects: 480
Study: 38188333

Group type: EXPERIMENTAL
Intervention: Participatory 'A'rt-Based Activity
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 112
Study: 38188343

Group type: EXPERIMENTAL
Intervention: HB-adMSCs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38188344

Group type: EXPERIMENTAL
Intervention: Local thermotherapy via an electric heat pad in the thorax (target temperature range 39.5–42°C) continuously for 90 minutes, twice daily, for 5 days
Number of subjects: 105

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 105
Study: 38188467

Group type: EXPERIMENTAL
Intervention: TQB2450 (1-30 mg/kg, intravenous once every 3 weeks)
Number of subjects: 40
Study: 38188539

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (0.5 mg/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 40
Study: 38188690

Group type: EXPERIMENTAL
Intervention: Leritrelvir 400 mg TID for 5 days
Number of subjects: 1359

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1359

Group type: EXPERIMENTAL
Intervention: Leritrelvir
Number of subjects: 1359
Study: 38189125

Group type: EXPERIMENTAL
Intervention: Referral to community-based rehabilitation (physical, occupational, or speech therapy) at discharge
Number of subjects: 10702

Group type: EXPERIMENTAL
Intervention: Referral to physical therapy
Number of subjects: 10702

Group type: EXPERIMENTAL
Intervention: Referral to occupational therapy
Number of subjects: 10702

Group type: EXPERIMENTAL
Intervention: Referral to speech therapy
Number of subjects: 10702

Group type: EXPERIMENTAL
Intervention: Patient-level predictors of referral
Number of subjects: 10702

Group type: EXPERIMENTAL
Intervention: Hospital referral rates
Number of subjects: 10702

Group type: EXPERIMENTAL
Intervention: County-level predictor
Number of subjects: 10702
Study: 38189180

Group type: EXPERIMENTAL
Intervention: sasanlimab plus BCG (induction ± maintenance)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: BCG alone
Number of subjects: 1000
Study: 38189182

Group type: EXPERIMENTAL
Intervention: Music-based caregiving (MBC)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 279
Study: 38189492

Group type: EXPERIMENTAL
Intervention: Oral vitamin B supplementation
Number of subjects: 984

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 984
Study: 38189593

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 4535

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 4535

Group type: EXPERIMENTAL
Intervention: Regional citrate
Number of subjects: 4535
Study: 38189649

Group type: EXPERIMENTAL
Intervention: Post-ICU subjective mental health assessment
Number of subjects: 855

Group type: EXPERIMENTAL
Intervention: Post-ICU subjective functional health assessment
Number of subjects: 855

Group type: EXPERIMENTAL
Intervention: ICU length of stay
Number of subjects: 855

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 855

Group type: EXPERIMENTAL
Intervention: Time after discharge
Number of subjects: 855
Study: 38189764

Group type: EXPERIMENTAL
Intervention: Image Guided Programming (IGP)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Clinical Standard Care (CSC)
Number of subjects: 32
Study: 38189778

Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA and FLU-QIV (Co-Ad group)
Number of subjects: 885

Group type: COMPARATOR
Intervention: FLU-QIV (SA group)
Number of subjects: 885

Group type: EXPERIMENTAL
Intervention: Both groups (Co-Ad and SA)
Number of subjects: 885
Study: 38189853

Group type: EXPERIMENTAL
Intervention: Preoperative telehealth call
Number of subjects: 126

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 126
Study: 38189868

Group type: EXPERIMENTAL
Intervention: Total Ankle Replacement (TAR)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Ankle Fusion (AF)
Number of subjects: 282
Study: 38189973

Group type: EXPERIMENTAL
Intervention: Optometric exam
Number of subjects: 708
Study: 38189999

Group type: EXPERIMENTAL
Intervention: Early D/LT group (patients who died or had undergone LT within 1 year after KP, n=35)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (patients who survived through the native liver more than 1 year after KP, n=49)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Nomogram based on independent variables (age at KP, jaundice clearance speed 1 month after KP, early-onset PC, sex, APRI, weight at KP)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Kaplan-Meier (K-M) curve
Number of subjects: 112
Study: 38190001

Group type: EXPERIMENTAL
Intervention: Taldefgrobep alfa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38190027

Group type: EXPERIMENTAL
Intervention: Chronic ocular pain group
Number of subjects: 38

Group type: COMPARATOR
Intervention: No chronic ocular pain group
Number of subjects: 38
Study: 38190051

Group type: EXPERIMENTAL
Intervention: Older paternal age (≥30 years)
Number of subjects: 16114

Group type: COMPARATOR
Intervention: Paternal age <30 years
Number of subjects: 16114
Study: 38190054

Group type: EXPERIMENTAL
Intervention: PEERS intervention program
Number of subjects: 100
Study: 38190077

Group type: EXPERIMENTAL
Intervention: PP1M (fixed-dose, 50, 75, 100, or 150 mg eq.)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: PP3M (fixed-dose, 175, 263, 350, or 525 mg eq.)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Baseline CGI-S total score
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Reduction in PANSS and CGI-S scores at week 13
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Stabilization criteria
Number of subjects: 296
Study: 38190119

Group type: EXPERIMENTAL
Intervention: Higher predonation BMI
Number of subjects: 1042

Group type: EXPERIMENTAL
Intervention: Higher waist circumference (WC)
Number of subjects: 1042
Study: 38190136

Group type: EXPERIMENTAL
Intervention: Argatroban (60 mg per day for 2 days, followed by 20 mg per day for 5 days) in addition to standard therapy (oral mono or dual antiplatelet therapy)
Number of subjects: 628

Group type: COMPARATOR
Intervention: Control group (standard therapy only)
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Argatroban
Number of subjects: 628

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 628
Study: 38190202

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-Physical Activity (non-PA) days
Number of subjects: 0
Study: 38190226

Group type: EXPERIMENTAL
Intervention: Feedback version of the e-12HR app
Number of subjects: 71

Group type: COMPARATOR
Intervention: Nonfeedback version of the e-12HR app
Number of subjects: 71
Study: 38190242

Group type: EXPERIMENTAL
Intervention: RE-PACT intervention (action planning, rapid clinical response, weekly SMS text messaging surveillance)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: RE-PACT intervention
Number of subjects: 90

Group type: COMPARATOR
Intervention: Usual care through the complex care clinical program
Number of subjects: 90
Study: 38190278

Group type: EXPERIMENTAL
Intervention: Prenatal counseling on the maternal health benefits of lactation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no prenatal counseling)
Number of subjects: 0
Study: 38190338

Group type: EXPERIMENTAL
Intervention: Loss-of-Resistance (LOR) technique
Number of subjects: 117

Group type: COMPARATOR
Intervention: Dynamic Pressure-Sensing (DPS) technology
Number of subjects: 117
Study: 38190373

Group type: EXPERIMENTAL
Intervention: Flexible proprioceptive strategy
Number of subjects: 47

Group type: COMPARATOR
Intervention: Rigid proprioceptive strategy
Number of subjects: 47
Study: 38190492

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 38190578

Group type: EXPERIMENTAL
Intervention: Bevacizumab (B) added to temozolomide (T), irinotecan-temozolomide (IT), or topotecan-temozolomide (TTo)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Temozolomide (T), irinotecan-temozolomide (IT), or topotecan-temozolomide (TTo) without Bevacizumab (B)
Number of subjects: 160
Study: 38190582

Group type: EXPERIMENTAL
Intervention: FoundationOne Liquid Companion Diagnostic (F1LCDx) assay
Number of subjects: 269

Group type: COMPARATOR
Intervention: Standard tissue testing
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: NGS ctDNA analysis
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Blood-based NGS ctDNA assay
Number of subjects: 269
Study: 38190642

Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir (LPV/r) oral solution
Number of subjects: 28
Study: 38190701

Group type: EXPERIMENTAL
Intervention: Higher Molecular Injury at Diagnosis of Acute Cellular Rejection
Number of subjects: 0
Study: 38190832

Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin + rituximab + lenalidomide (Pola+R+Len)
Number of subjects: 57
Study: 38190964

Group type: EXPERIMENTAL
Intervention: Kinesio taping with active release technique for 4 weeks (3 days/week)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Kinesio taping alone for 4 weeks (5 days/week)
Number of subjects: 32
Study: 38191014

Group type: EXPERIMENTAL
Intervention: Telephone outreach
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Secure messaging outreach
Number of subjects: 604

Group type: COMPARATOR
Intervention: Mailed letter outreach
Number of subjects: 604
Study: 38191203

Group type: EXPERIMENTAL
Intervention: Paediatric telemedicine service (TMDS)
Number of subjects: 391
Study: 38191245

Group type: EXPERIMENTAL
Intervention: Operative treatment including reduction and fixation of the syndesmosis
Number of subjects: 120

Group type: COMPARATOR
Intervention: Non-operative treatment with an orthosis
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 120

Group type: COMPARATOR
Intervention: Non-operative treatment
Number of subjects: 120
Study: 38191246

Group type: EXPERIMENTAL
Intervention: SKYPE programme (physiotherapy, yoga, and patient education)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 38191248

Group type: EXPERIMENTAL
Intervention: MABC clinics
Number of subjects: 441
Study: 38191249

Group type: EXPERIMENTAL
Intervention: Functional Activity Scoring Tool (FAST)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patient-Specific Functional Scale (PSFS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Knee Injury and Osteoarthritis Outcome Score (KOOS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Global Rating of Change (GROC) scale
Number of subjects: 0
Study: 38191268

Group type: EXPERIMENTAL
Intervention: Ebastine 20 mg
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study: 38191317

Group type: EXPERIMENTAL
Intervention: MPI Brasil app (provides information about PIP, therapeutic alternatives and deprescribing)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: MPI Brasil app
Number of subjects: 146

Group type: COMPARATOR
Intervention: MedSUS app (provides general information about medications)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 146
Study: 38191318

Group type: EXPERIMENTAL
Intervention: Digital test battery from Mindmore
Number of subjects: 50

Group type: COMPARATOR
Intervention: Analog test battery from ISPOCD
Number of subjects: 50
Study: 38191347

Group type: EXPERIMENTAL
Intervention: Asymmetrical high-flow nasal cannula (Optiflow® Duet system)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard high-flow nasal cannula
Number of subjects: 20
Study: 38191370

Group type: EXPERIMENTAL
Intervention: Active iTBS (intermittent theta burst stimulation)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Sham iTBS
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Open-label low-frequency right-sided (1 Hz) stimulation
Number of subjects: 230
Study: 38191406

Group type: EXPERIMENTAL
Intervention: Intensive interactive, professionally facilitated, 8- to 10-h Sanyas ICS training
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Brief 1-h anti-bias training adapted to address anti-Indigenous bias
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control continuing medical education time-attention matched to the intensive training
Number of subjects: 58
Study: 38191436

Group type: COMPARATOR
Intervention: Control group receiving no treatment
Number of subjects: 1397

Group type: EXPERIMENTAL
Intervention: Simplified treatment receiving 1 sachet of RUTF daily until WAZ ≥-3 for 2 visits
Number of subjects: 1397

Group type: EXPERIMENTAL
Intervention: Standard treatment receiving RUTF according to WHZ category
Number of subjects: 1397
Study: 38191449

Group type: EXPERIMENTAL
Intervention: L-carnitine 1000 mg (3 tablets daily) for 6 weeks
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo (3 tablets daily) for 6 weeks
Number of subjects: 110
Study: 38191529

Group type: EXPERIMENTAL
Intervention: 7 × 19 CAR-T cells
Number of subjects: 39
Study: 38191536

Group type: EXPERIMENTAL
Intervention: Mailed fecal immunochemical test (FIT) outreach and patient navigation program
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Mailed FIT outreach supported by clinics, health plans, and vendors
Number of subjects: 28
Study: 38191561

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon (AcoArt Orchid)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Plain balloon catheter
Number of subjects: 244
Study: 38191589

Group type: EXPERIMENTAL
Intervention: Traditional Pilates (TP)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Nontraditional Pilates (NTP)
Number of subjects: 32
Study: 38191613

Group type: EXPERIMENTAL
Intervention: Atezolizumab monotherapy followed by four cycles of atezolizumab plus docetaxel, oxaliplatin and capecitabine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus chemotherapy
Number of subjects: 21
Study: 38191615

Group type: EXPERIMENTAL
Intervention: Toripalimab plus nab-paclitaxel (n = 353)
Number of subjects: 531

Group type: COMPARATOR
Intervention: Placebo plus nab-paclitaxel (n = 178)
Number of subjects: 531
Study: 38191814

Group type: EXPERIMENTAL
Intervention: Laparoscopic right hemicolectomy with various anastomosis techniques (intracorporeal, side-to-side, isoperistaltic)
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Robotic approach
Number of subjects: 788
Study: 38191821

Group type: COMPARATOR
Intervention: Magnetization transfer ratio (MTR) in patients with T2D (0.211 ± 0.07)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Magnetization transfer ratio (MTR) in patients with T1D
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Magnetization transfer ratio (MTR) in patients with T2D
Number of subjects: 52
Study: 38191968

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) surgery
Number of subjects: 30
Study: 38192233

Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg subcutaneously at weeks 0 and 4
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg subcutaneously every 12 weeks after week 12
Number of subjects: 220
Study: 38192247

Group type: EXPERIMENTAL
Intervention: Automated retinal oximetry in patients with significant carotid stenosis
Number of subjects: 50

Group type: COMPARATOR
Intervention: Non-stenotic vessels (control group)
Number of subjects: 50
Study: 38192435

Group type: EXPERIMENTAL
Intervention: ADPKD-Impact Scale (ADPKD-IS)
Number of subjects: 3409

Group type: EXPERIMENTAL
Intervention: ADPKD-Urinary Impact Scale (ADPKD-UIS)
Number of subjects: 3409

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes (PROs)
Number of subjects: 3409

Group type: EXPERIMENTAL
Intervention: Quality of life assessment
Number of subjects: 3409
Study: 38192588

Group type: EXPERIMENTAL
Intervention: Hearing impairment (≥25 dB threshold)
Number of subjects: 7135
Study: 38192592

Group type: EXPERIMENTAL
Intervention: Durvalumab 1500 mg every 28 days until progression or unacceptable toxicity
Number of subjects: 50
Study: 38193018

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 164

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 164
Study: 38193069

Group type: EXPERIMENTAL
Intervention: Emicizumab prophylaxis
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Menstruation-related quality of life
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Menstruation heaviness
Number of subjects: 3
Study: 38193158

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT), 2 to 4 sessions
Number of subjects: 3
Study: 38193250

Group type: EXPERIMENTAL
Intervention: PALLiON intervention (physician education program, patient-centred care pathway, patient symptom reporting)
Number of subjects: 616

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: PALLiON intervention
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: PALLiON intervention and Usual care (control)
Number of subjects: 616
Study: 38193259

Group type: EXPERIMENTAL
Intervention: Cholera toxin sensitization
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Oil emulsion sensitization
Number of subjects: 45

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 45
Study: 38193327

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 5178
Study: 38193336

Group type: EXPERIMENTAL
Intervention: Care2Sleep intervention (n=15 dyads)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Information-only control group (n=15 dyads)
Number of subjects: 30
Study: 38193426

Group type: EXPERIMENTAL
Intervention: 10 kHz spinal cord stimulation (SCS) plus conventional medical management (CMM)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Conventional medical management (CMM) alone
Number of subjects: 216
Study: 38193596

Group type: EXPERIMENTAL
Intervention: Damoctocog alfa pegol (BAY 94-9027, Jivi®)
Number of subjects: 25
Study: 38194016

Group type: EXPERIMENTAL
Intervention: Serplulimab (0.3, 1.0, 3.0, and 10.0 mg/kg every 2 weeks in 28-day cycles for up to 2 years)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Serplulimab
Number of subjects: 29
Study: 38194047

Group type: EXPERIMENTAL
Intervention: Dupilumab (200/300 mg) every 4 weeks for 16 weeks
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo every 4 weeks for 16 weeks
Number of subjects: 125
Study: 38194118

Group type: EXPERIMENTAL
Intervention: mHealth intervention for cancer prevention education
Number of subjects: 0
Study: 38194162

Group type: EXPERIMENTAL
Intervention: Efbemalenograstim alfa (80, 240, or 320 µg/kg for TC; 240 or 320 µg/kg for TAC)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Pegfilgrastim (6 mg)
Number of subjects: 232
Study: 38194231

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed by chemoradiation
Number of subjects: 304

Group type: COMPARATOR
Intervention: Chemoradiation followed by consolidation chemotherapy
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Clinical tumor response grade (CCR vs NCR)
Number of subjects: 304